Quiz answer: >> 1. Generic polysaccharide drugs 2. Generic polypeptide drugs 3. Generic glycoprotein drugs What is all this in reference to? << This is the progression in MNTA’s business model from easiest to hardest. Step #1 has already reached the ANDA submission stage for generic Lovenox. Step #2 is under development with partner NVS to create a generic version of Copaxone. An ANDA will follow. Step #3 is in early development using two undisclosed glycoproteins designated by NVS. The regulatory path is not yet established.